Abstract
Introduction
Variability in usage and definition of data characteristics in previous cohort studies on unruptured intracranial aneurysms (UIA) complicated pooling and proper interpretation of these data. The aim of the National Institute of Health/National Institute of Neurological Disorders and Stroke UIA and Subarachnoid Hemorrhage (SAH) Common Data Elements (CDE) Project was to provide a common structure for data collection in future research on UIA and SAH.
Methods
This paper describes the development and summarization of the recommendations of the working groups (WGs) on UIAs, which consisted of an international and multidisciplinary panel of cerebrovascular specialists on research and treatment of UIAs. Consensus recommendations were developed by review of previously published CDEs for other neurological diseases and the literature on UIAs. Recommendations for CDEs were classified by priority into ‘Core,’ ‘Supplemental—Highly Recommended,’ ‘Supplemental,’ and ‘Exploratory.’
Results
Ninety-one CDEs were compiled; 69 were newly created and 22 were existing CDEs. The CDEs were assigned to eight subcategories and were classified as Core (8), Supplemental—Highly Recommended (23), Supplemental (25), and Exploratory (35) elements. Additionally, the WG developed and agreed on a classification for aneurysm morphology.
Conclusion
The proposed CDEs have been distilled from a broad pool of characteristics, measures, or outcomes. The usage of these CDEs will facilitate pooling of data from cohort studies or clinical trials on patients with UIAs.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Around 3% of the adult global population has unruptured intracranial aneurysms (UIAs) [1]. The increased usage and improved quality of cranial imaging have resulted in more frequent detection of these lesions. UIAs can remain clinically asymptomatic, present with focal neurological deficits from local mass effect or ischemia, or they may rupture. Rupture of an aneurysm results in aneurysmal subarachnoid hemorrhage (SAH), which has a case fatality rate up to 35% and a high risk for permanent neurological disabilities as well as neuropsychological disorders in survivors [2, 3].
Previous meta-analyses on development or rupture of UIAs have been hampered by varying definitions of risk factors, which sometimes led to inconsistent results [4, 5]. In a pooled analysis of individual patient data from six prospective cohort studies, six easily retrievable predictors enabled the calculation of the 5-year risk of aneurysm rupture: population, hypertension, patient age, aneurysm size, earlier SAH from another aneurysm, and aneurysm site. However, several other potential risk factors, such as smoking status during follow-up or aneurysm morphology, could not be included in the risk score because data were not collected at all or with varying methods [5, 6].
The Common Data Elements (CDE) project for standardizing data for neurological clinical research was initiated by cerebrovascular clinicians and scientists under the auspices of The National Institute of Neurological Disorders and Stroke to facilitate pooling and comparison of such data on cerebrovascular disease.
Process for Selecting CDEs
For a description of the UIA and SAH CDE project, we refer to the main article of this project [7]. For development of CDEs for the WG ‘UIA’ of ‘UIA and SAH,’ a multidisciplinary and international group of nine cerebrovascular specialists on research and treatment of UIAs was assembled by the two work group (WG) co-chairs (NE, GJER) (Fig. 1). Following systematic review and collection of the current data on UIAs by the two co-chairs, existing CDEs on ischemic stroke were integrated in data sheets. These were circulated to all WG members and subsequently reviewed, expanded, or modified by each member. Additionally, the WG developed a proposal for classification of aneurysm morphology based on current data. Further, CDEs that apply to multiple WGs (e.g., aneurysm size or location in the imaging WG) were crosschecked and/or adapted with these subcommittees to exclude heterogeneous definitions of the same CDEs.
Finally, the CDEs were categorized into four groups: (1) Core CDEs—elements which can be consistently collected across studies and which should be employed in studies concerning the corresponding particular disease or therapeutic area; (2) Supplemental—Highly Recommended CDEs—elements that are essentially based on certain conditions or study types in clinical research studies and that are strongly recommended for the specific disease or therapeutic area; (3) Supplemental CDEs—elements that are commonly collected in clinical research studies, but whose relevance depends on the study design or type of research; and 4. Exploratory CDEs—elements which are reasonable to use, but whose validity is yet limited due to insufficient availability and validation of data. The categorization was proposed by the two co-chairs, and after another round of review and revision of all CDEs, all the WG members agreed on the final proposal of the UIA CDEs. These findings were presented at the 4th Neurocritical Care Research Conference in Houston, Texas, May 2016, for further review and revision within the SAH CDE research group. The final version of the CDEs was once more circulated within the WG, and upon agreement, the final case report forms were developed.
Common Data Elements Overview
The ‘UIA’ WG collected 91 CDEs, 69 new CDEs, and 22 already established CDEs where only minor changes had to be made for our purposes. The CDEs were divided into eight categories: demographics, reason of medical consult and diagnosis, clinical symptoms and assessment at baseline, risk factors, concomitant medications, concomitant diseases, radiological findings, as well as management of unruptured aneurysms. Each CDE was assigned a specific identification number, a CDE name, variable name, definition, classification, permissible values, a code name, a code description and if necessary, a unit of measure and a question text.
The CDEs were classified as 8 Core (see below), 23 Supplemental—Highly Recommended, 25 Supplemental, and 35 Exploratory elements (Tables 1–8).
Description of Core CDEs
Demographics (Table 1).
-
Risk factors (Table 4).
-
Hypertension (defined as systolic blood pressure greater than or equal to 140 mmHg or greater than or equal to 90 mmHg diastolic in adults or systolic or diastolic blood pressure above the 95 percentile in children) (preexisting CDE) [5, 8, 11,12,13].
-
Tobacco smoking status: (a) never, (b) former (including start and end date of smoking), (c) current (including starting date) and (d) unknown (modified CDE) [1, 9,10,11,12,13,14,15,16,17].
Radiological findings (Table 7).
-
Anatomical aneurysm site based on angiography (modified CDE) [5, 9, 18,19,20,21,22,23,24,25,26].
-
Maximum aneurysm diameter (in mm) in any direction (new CDE) [5, 8, 9, 16,17,18,19,20, 22,23,24,25,26,27,28,29].
-
Maximum aneurysm height (in mm) perpendicular to aneurysm neck (new CDE) [30].
-
Maximum aneurysm width (in mm) perpendicular to aneurysm height (new CDE) [30].
-
Aneurysm morphology type: (a) regular, (b) bleb, (c) daughter-sac/multilobed aneurysm (new CDE, Fig. 2) [20,21,22,23, 27, 30,31,32,33].
Description of UIA CDEs
For ‘reason of medical consult and diagnosis,’ one CDE with eight permissible values was established (Table 2). The subtopic ‘clinical symptoms and assessment at baseline’ contains eight CDEs, of which three were novel and the remaining were edited (Table 3). Twelve CDEs on ‘risk factors’ were established, comprised of six novel and six reutilized CDE. Permissible values and further information were added to the CDE ‘tobacco smoke history status’ as a core item (Table 4). Additionally, a classification concerning the morphology of an aneurysm was established (Fig. 2). There are 10 CDEs in the subtopic ‘concomitant medications’, of which seven were novel and three were modified (Table 5). The subject area ‘concomitant diseases’ contains 21 novel CDEs and three already established CDEs (Table 6). For ‘radiological findings,’ we compiled 27 CDEs, out of these the CDE ‘imaging modality vessel imaging angiography type’ was reused and permissible values were added to the Stroke CDE ‘imaging vessel angiography aneurysm’ (Table 7). Six novel CDEs were established for ‘UIA management’ (Table 8).
Limitations
This project has limitations: We identified and defined numerous data elements in the setting of UIAs, based on existing and/or most commonly used definitions. We balanced between very detailed definitions, which would decrease the feasibility of using these, and broad definitions, which are easier to use in clinical practice, but may provide less scientific details. Thus, the definitions and their scientific implication remain uncertain and need to be validated prospectively. Further, for several CDEs, we had to define limits or cut-off values. For example, for hypertension, we used the accepted definitions of the cardiac guidelines, a systolic pressure of 140 mmHg and a diastolic one of 90 mmHg, but it remains uncertain whether these cut-off values for hypertension are clinically relevant in terms of risk factor for growth or rupture. Further, a consensus approach was used to define and rank the individual importance of data elements based on existing literature. Thus, other potentially relevant data elements suggested by experimental or case–control studies could not be included at present because of the lack of validated measurement tools or grading scales for such outcomes (e.g., aneurysm wall inflammation in imaging studies). Additionally, the WG established and agreed on a novel classification system for aneurysm morphology, for which there were no immediate data from the previous cohort or case–control studies to support this exact classification. However, since three-dimensional aneurysm morphologies are difficult to measure or to describe in standardized manner, the WG agreed on a two-dimensional classification as a basis for further research. Lastly, the established CDEs on UIAs may need to be adapted or even expanded, e.g., with neurocognitive outcome measures and grading scales in patients undergoing preventive UIA repair or follow-up imaging in the future, if there are sufficient data to support this. Despite these limitations, standardized collection of the proposed CDEs will at least provide data on whether the CDEs as currently defined are risk factors for the development and rupture of intracranial aneurysms.
Next Steps/Future Work
Future clinical studies need to test and validate the sensitivity and relative importance of the UIA CDEs established. Furthermore, data should be derived from more advanced imaging modalities in the setting of UIAs including their standardized measurement and morphological analysis.
Conclusions
We defined and categorized a total of 91 CDEs, of which 71 were novel for UIAs. These CDEs on UIAs could serve as a basis to standardize future studies and thereby help to harmonize data across studies. However, the CDEs remain to be validated, adapted, and updated in the future based on novel data for optimizing already existing CDEs and for establishing new CDEs.
Change history
04 October 2021
A Correction to this paper has been published: https://doi.org/10.1007/s12028-021-01346-6
References
Vlak MH, Rinkel GJ, Greebe P, Algra A. Risk of rupture of an intracranial aneurysm based on patient characteristics: a case–control study. Stroke. 2013;44(5):1256–9.
Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42.
Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology. 2010;74(19):1494–501.
Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke. 2005;36(12):2773–80.
Greving JP, Wermer MJ, Brown RD Jr., Morita A, Juvela S, Yonekura M, et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet Neurol. 2014;13(1):59–66.
Backes D, Rinkel GJE, Greving JP, Velthuis BK, Murayama Y, Takao H, et al. ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. Neurology. 2017;88(17):1600–6.
Damani R, Mayer S, Dhar R, Martin RH, Nyquist P, Olson DM, et al. Common data element for unruptured intracranial aneurysm and subarachnoid hemorrhage: recommendations from assessments and clinical examination workgroup/subcommittee. Neurocrit Care. 2019. https://doi.org/10.1007/s12028-019-00736-1.
Sonobe M, Yamazaki T, Yonekura M, Kikuchi H. Small unruptured intracranial aneurysm verification study: SUAVe study, Japan. Stroke. 2010;41(9):1969–77.
Juvela S, Poussa K, Lehto H, Porras M. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. Stroke. 2013;44(9):2414–21.
Lindgren AE, Raisanen S, Bjorkman J, Tattari H, Huttunen J, Huttunen T, et al. De novo aneurysm formation in carriers of saccular intracranial aneurysm disease in eastern Finland. Stroke. 2016;47(5):1213–8.
Vlak MH, Rinkel GJ, Greebe P, Algra A. Independent risk factors for intracranial aneurysms and their joint effect: a case-control study. Stroke. 2013;44(4):984–7.
Wermer MJ, van der Schaaf IC, Velthuis BK, Algra A, Buskens E, Rinkel GJ. Follow-up screening after subarachnoid haemorrhage: frequency and determinants of new aneurysms and enlargement of existing aneurysms. Brain. 2005;128(Pt 10):2421–9.
Etminan N, Beseoglu K, Steiger HJ, Hanggi D. The impact of hypertension and nicotine on the size of ruptured intracranial aneurysms. J Neurol Neurosurg Psychiatry. 2011;82(1):4–7.
Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011;10(7):626–36.
Juvela S, Poussa K, Porras M. Factors affecting formation and growth of intracranial aneurysms: a long-term follow-up study. Stroke. 2001;32(2):485–91.
Korja M, Lehto H, Juvela S. Lifelong rupture risk of intracranial aneurysms depends on risk factors: a prospective Finnish cohort study. Stroke. 2014;45(7):1958–63.
Igase M, Igase K, Kohara K, Yamashita S, Fujisawa M, Katagi R, et al. Visit-to-visit variability in systolic blood pressure is a novel risk factor for the growth of intracranial aneurysms. Cerebrovasc Dis. 2013;36(5–6):401–6.
Juvela S, Korja M. Intracranial aneurysm parameters for predicting a future subarachnoid hemorrhage: a long-term follow-up study. Neurosurgery. 2017;81(3):432–40.
Wiebers DO, Whisnant JP, Huston J III, Meissner I, Brown RD Jr, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–10.
Morita A, Kirino T, Hashi K, Aoki N, Fukuhara S, Hashimoto N, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012;366(26):2474–82.
Schneiders JJ, Marquering HA, van Ooij P, van den Berg R, Nederveen AJ, Verbaan D, et al. Additional value of intra-aneurysmal hemodynamics in discriminating ruptured versus unruptured intracranial aneurysms. AJNR Am J Neuroradiol. 2015;36(10):1920–6.
Backes D, Rinkel GJ, Laban KG, Algra A, Vergouwen MD. Patient- and aneurysm-specific risk factors for intracranial aneurysm growth: a systematic review and meta-analysis. Stroke. 2016;47(4):951–7.
Murayama Y, Takao H, Ishibashi T, Saguchi T, Ebara M, Yuki I, et al. Risk analysis of unruptured intracranial aneurysms: prospective 10-year cohort study. Stroke. 2016;47(2):365–71.
Ishibashi T, Murayama Y, Urashima M, Saguchi T, Ebara M, Arakawa H, et al. Unruptured intracranial aneurysms: incidence of rupture and risk factors. Stroke. 2009;40(1):313–6.
Matsubara S, Hadeishi H, Suzuki A, Yasui N, Nishimura H. Incidence and risk factors for the growth of unruptured cerebral aneurysms: observation using serial computerized tomography angiography. J Neurosurg. 2004;101(6):908–14.
Miyazawa N, Akiyama I, Yamagata Z. Risk factors for growth of unruptured intracranial aneurysms: follow-up study by serial 0.5-T magnetic resonance angiography. Neurosurgery. 2006;58(6):1047–53 (discussion -53).
Jing L, Fan J, Wang Y, Li H, Wang S, Yang X, et al. Morphologic and hemodynamic analysis in the patients with multiple intracranial aneurysms: ruptured versus unruptured. PLoS ONE. 2015;10(7):e0132494.
Kashiwazaki D, Kuroda S. Size ratio can highly predict rupture risk in intracranial small (< 5 mm) aneurysms. Stroke. 2013;44(8):2169–73.
Burns JD, Huston J III, Layton KF, Piepgras DG, Brown RD Jr. Intracranial aneurysm enlargement on serial magnetic resonance angiography: frequency and risk factors. Stroke. 2009;40(2):406–11.
Bor AS, Tiel Groenestege AT, terBrugge KG, Agid R, Velthuis BK, Rinkel GJ, et al. Clinical, radiological, and flow-related risk factors for growth of untreated, unruptured intracranial aneurysms. Stroke. 2015;46(1):42–8.
de Rooij NK, Velthuis BK, Algra A, Rinkel GJ. Configuration of the circle of Willis, direction of flow, and shape of the aneurysm as risk factors for rupture of intracranial aneurysms. J Neurol. 2009;256(1):45–50.
Lindgren AE, Koivisto T, Bjorkman J, von Und Zu Fraunberg M, Helin K, Jaaskelainen JE, et al. Irregular shape of intracranial aneurysm indicates rupture risk irrespective of size in a population-based cohort. Stroke. 2016;47(5):1219–26.
Backes D, Vergouwen MD, Velthuis BK, van der Schaaf IC, Bor AS, Algra A, et al. Difference in aneurysm characteristics between ruptured and unruptured aneurysms in patients with multiple intracranial aneurysms. Stroke. 2014;45(5):1299–303.
Acknowledgements
The views expressed here are those of the authors and do not represent those of the National Institutes of Health (NIH), the National Institute of Neurological Disorders and Stroke (NINDS), or the US Government. Logistical support for this project was provided in part through NIH Contract HHSN271201200034C, the Intramural Research Program of the NIH, NLM, The Neurocritical Care Society, and the CHI Baylor St Luke’s Medical Center in Houston, TX. The development of the NINDS SAH CDEs was made possible thanks to the great investment of time and effort of WG members and the members of the NINDS CDE Project and NLM CDE project teams participating from 2015–2017.
Author information
Authors and Affiliations
Consortia
Contributions
KAMH, NE, and GR contributed to protocol development, and manuscript writing/editing; AA, RA-SS, JF, DH, SJ, DL, PM, and AM contributed to manuscript writing/editing. The corresponding author confirms that authorship requirements have been met, the final manuscript was approved by ALL authors, and that this manuscript has not been published elsewhere and is not under consideration by another journal. The UIA and SAH CDEs project adhered to ethical guidelines.
Corresponding author
Ethics declarations
Source of support
None.
Conflict of interest
All authors have no conflicts of interest.
Ethical approval/informed consent
This article does not contain any studies with human participants or animals performed by any of the authors.
UIA and SAH Working Group Members
Steering Committee
Jose I Suarez, MD, FNCS, FANA, Johns Hopkins University School of Medicine, Baltimore, MD, co-Chair; R Loch Macdonald, MD, PhD, University of Toronto, Toronto, ON, Canada, co-Chair; Sepideh Amin-Hanjani, MD—University of Illinois at Chicago, Chicago, IL; Robert D. Brown, Jr., MD, MPH—Mayo Clinic, Rochester, MN; Airton Leonardo de Oliveira Manoel, MD, PhD—University of Toronto, Toronto, Ontario, Canada; Colin P Derdeyn, MD, FACR—University of Iowa, Carver College of Medicine, Iowa City, IA; Nima Etminan, MD—University Hospital Mannheim, Mannheim, Germany; Emanuela Keller, MD—University of Zurich, Zurich, Switzerland; Peter D. LeRoux, MD, FACS—Main Line Health, Wynnewood, PA; Stephan Mayer, MD—Henry Ford Hospital, Detroit, MI; Akio Morita, MD, PhD—Nippon Medical School, Tokyo, Japan; Gabriel Rinkel, MD—University Medical Center, Utrecht, The Netherlands; Daniel Rufennacht, MD—Klinik Hirslanden, Zurich, Switzerland; Martin N. Stienen, MD, FEBNS—University of Zurich, Zurich, Switzerland; James Torner, MSc, PhD—University of Iowa, Iowa City, IA; Mervyn D.I. Vergouwen, MD, PhD—University Medical Center, Utrecht, The Netherlands; George K. C. Wong, MD—Chinese University of Hong Kong, Shatin, Hong Kong.
Subject Characteristics Working Group
Robert D. Brown, Jr., MD, MPH—Mayo Clinic, Rochester, MN, co-Chair; Akio Morita, MD, PhD—Nippon Medical School, Tokyo, Japan, co-Chair; Philippe Bijlenga, MD, PhD, Geneva University Hospital, Geneva, Switzerland (Superuser); Nerissa Ko, MD; Cameron G McDougall, MD; J Mocco, MS, MD; Yuuichi Murayama, MD; Marieke J H Werner, MD, PhD.
Assessments and Examinations Working Group
Stephan Mayer, MD—Henry Ford Hospital, Detroit, MI, co-Chair; Jose I Suarez, MD, FNCS, FANA, The Johns Hopkins University School of Medicine, Baltimore, MD, co-Chair; Rahul Damani, MD, MPH, Baylor College of Medicine, Houston, TX (Superuser); Joseph Broderick, MD; Raj Dhar, MD, FRCPC; Edward C Jauch, MD, MS, FACEP, FAHA; Peter J Kirkpatrick; Renee H Martin, PhD; J Mocco, MS, MD; Susanne Muehlschlegel, MD, MPH; Tatsushi Mutoh, MD, DVM, PhD; Paul Nyquist, MD, MPH; Daiwai Olson, RN, PhD; Jorge H Mejia-Mantilla, MD, MSc.
Hospital Course and Acute Therapies Working Group
Sepideh Amin-Hanjani, MD—University of Illinois at Chicago, Chicago, IL, co-Chair; Airton Leonardo de Oliveira Manoel, MD, PhD—University of Toronto, Toronto, Ontario, Canada, co-Chair (Superuser); Mathieu van der Jagt, MD, PhD, Erasmus Medical Center, Rotterdam, The Netherlands (Superuser); Nicholas Bambakidis, MD; Gretchen Brophy, PharmD, BCPS, FCCP, FCCM, FNCS; Ketan Bulsara, MD; Jan Claassen, MD, PhD; E Sander Connolly, MD, FACS; S Alan Hoffer, MD; Brian L Hoh, MD, FACS; Robert G Holloway, MD, MPH; Adam Kelly, MD; Stephan Mayer, MD; Peter Nakaji, MD; Alejandro Rabinstein, MD; Jose I Suarez, MD, FNCS, FANA; Peter Vajkoczy, MD; Mervyn D. I. Vergouwen, MD, PhD; Henry Woo, MD; Gregory J Zipfel, MD.
Biospecimens and Biomarkers Working Group
Emanuela Keller, MD—University of Zurich, Zurich, Switzerland, co-Chair (Superuser); R Loch Macdonald, MD, PhD, University of Toronto, Toronto, ON, Canada, co-Chair; Sherry Chou, MD, MMSc; Sylvain Doré, PhD, FAHA; Aaron S Dumont, MD; Murat Gunel, MD, FACS, FAHA; Hidetoshi Kasuya, MD; Alexander Roederer, PhD; Ynte Ruigrok, MD; Paul M Vespa, MD, FCCM, FAAN, FANA, FNCS; Asita Simone Sarrafzadeh-Khorrasani, PhD.
Imaging Working Group
Colin P Derdeyn, MD, FACR—University of Iowa, Carver College of Medicine, Iowa City, IA, co-Chair; Nima Etminan, MD University Hospital Mannheim, Mannheim, Germany, co-Chair; Katharina A. M. Hackenberg, MD, University Hospital Mannheim, Mannheim, Germany (Superuser); John Huston, III, MD; Timo Krings, MD, PhD, FRCPC; Giuseppe Lanzino, MD; Philip M Meyers, MD, FACR, FSIR, FAHA; Gabriel Rinkel, MD; Daniel Rufennacht, MD; Max Wintermark, MD.
Long-Term Therapies Working Group
James Torner, MSc, PhD—University of Iowa, Iowa City, IA, co-Chair (Superuser); George K. C. Wong, MD—Chinese University of Hong Kong, Shatin, Hong Kong, co-Chair (Superuser); Joseph Broderick, MD; Janis Daly, PhD, MS; Christopher Ogilvy, MD; Denise H Rhoney, PharmD, FCCP, FCCM, FNCS; YB Roos, PhD; Adnan Siddiqui, MD, PhD, FAHA.
Unruptured Intracranial Aneurysms Working Group
Nima Etminan, MD—University Hospital Mannheim, Mannheim, Germany, co-Chair; Gabriel Rinkel, MD—University Medical Center, Utrecht, The Netherlands, co-Chair; Katharina A. M. Hackenberg, MD, University Hospital Mannheim, Mannheim, Germany (Superuser); Ale Algra, MD, FAHA; Juhanna Frösen, MD; David Hasan, MD; Seppo Juvela, MD, PhD; David J Langer, MD; Philip M Meyers, MD, FACR, FSIR, FAHA; Akio Morita, MD, PhD; Rustam Al-Shahi Salman, MA, PhD, FRCP.
Outcomes and Endpoints Working Group
Martin N. Stienen, MD, FEBNS—University of Zurich, Zurich, Switzerland, co-Chair (Superuser); Mervyn D.I. Vergouwen, MD, PhD—University Medical Center, Utrecht, The Netherlands, co-Chair; Daniel Hanggi, MD; R Loch Macdonald, MD, PhD; Tom Schweizer, PhD; Johanna Visser-Meily, MD, PhD.
National Library of Medicine CDE Team
Liz Amos, MLIS, National Information Center on Health Services Research and Health Care Technology, National Library of Medicine; Christophe Ludet, MS, National Library of Medicine, Bethesda, MD.
NINDS CDE Team
Claudia Moy, PhD, NINDS, Bethesda, MD; Joanne Odenkirchen, MPH, NINDS, Bethesda, MD; Sherita Ala’i, MS, The Emmes Corporation, Rockville, MD; Joy Esterlitz, MS, The Emmes Corporation, Rockville, MD; Kristen Joseph, MA, The Emmes Corporation, Rockville, MD; Muniza Sheikh, MS, MBA, The Emmes Corporation, Rockville, MD.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article was updated to correct the tagging of Rustam Al-Shahi Salman’s name in the metadata.
Rights and permissions
About this article
Cite this article
Hackenberg, K.A.M., Algra, A., Al-Shahi Salman, R. et al. Definition and Prioritization of Data Elements for Cohort Studies and Clinical Trials on Patients with Unruptured Intracranial Aneurysms: Proposal of a Multidisciplinary Research Group. Neurocrit Care 30 (Suppl 1), 87–101 (2019). https://doi.org/10.1007/s12028-019-00729-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-019-00729-0